Rezension:

i'm fine good work sulfasalazine rheumatoid arthritis mechanism The market is increasingly moving away from injectabletreatments in favour of pills such as Novartis' Gilenya andBiogen Idec's Tecfidera, but Genzyme is hopeful Lemtrada'sability to durably reduce the risk of relapse of the diseasewill win it a slice of the market.

Bewertung: